(VIANEWS) – Ares Capital (ARCC), The Joint Corp. (JYNT), RadNet (RDNT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Ares Capital (ARCC)
32.4% sales growth and 6.51% return on equity
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.
Earnings Per Share
As for profitability, Ares Capital has a trailing twelve months EPS of $1.27.
PE Ratio
Ares Capital has a trailing twelve months price to earnings ratio of 14.28. Meaning, the purchaser of the share is investing $14.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.51%.
Sales Growth
Ares Capital’s sales growth is 42.1% for the current quarter and 32.4% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 40.5% and 30.4%, respectively.
2. The Joint Corp. (JYNT)
19.8% sales growth and 3.8% return on equity
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of January 27, 2021, the company operated approximately 550 locations in the United States. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Earnings Per Share
As for profitability, The Joint Corp. has a trailing twelve months EPS of $0.08.
PE Ratio
The Joint Corp. has a trailing twelve months price to earnings ratio of 200.5. Meaning, the purchaser of the share is investing $200.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Volume
Today’s last reported volume for The Joint Corp. is 74325 which is 24.62% below its average volume of 98603.
3. RadNet (RDNT)
9% sales growth and 8.02% return on equity
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, RadNet has a trailing twelve months EPS of $0.17.
PE Ratio
RadNet has a trailing twelve months price to earnings ratio of 164.53. Meaning, the purchaser of the share is investing $164.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.02%.
Yearly Top and Bottom Value
RadNet’s stock is valued at $27.97 at 16:22 EST, under its 52-week high of $28.13 and way higher than its 52-week low of $12.03.
4. Air Transport Services Group (ATSG)
7.6% sales growth and 14.36% return on equity
Air Transport Services Group, Inc., together with its subsidiaries, provides aircraft leasing and air cargo transportation and related services in the United States and internationally. The company offers aircraft, flight crews, aircraft maintenance, aircraft hull and liability insurance, and aviation fuel services; and aircraft maintenance and modification services, including airframe modification and heavy maintenance, component repairs, engineering services, and aircraft line maintenance. It also provides equipment maintenance services; cargo load transfer and package sorting services; crew training services; and airline express operation, line and heavy maintenance, and ground handling services. The company's ground support services include labor and management for cargo load transfer and sorting; design, installation, and maintenance of material handling equipment; leasing and maintenance of ground support equipment; and general facilities maintenance. In addition, it offers equipment installation and maintenance, vehicle maintenance and repair, jet fuel, and deicing services. Further, the company operates cargo and passenger transportation business; resells and brokers aircraft parts; and performs passenger-to-freighter and passenger-to-combi conversions of aircrafts. It provides its services to delivery companies, freight forwarders, airlines, air transportation, e-commerce, package delivery, and logistics industries, as well as government customers. As of December 31, 2021, the company's in-service aircraft fleet consisted of 107 owned aircraft and ten leased aircraft. The company was formerly known as ABX Holdings, Inc. Air Transport Services Group, Inc. was founded in 1980 and is based in Wilmington, Ohio.
Earnings Per Share
As for profitability, Air Transport Services Group has a trailing twelve months EPS of $2.22.
PE Ratio
Air Transport Services Group has a trailing twelve months price to earnings ratio of 8.86. Meaning, the purchaser of the share is investing $8.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.36%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Air Transport Services Group’s EBITDA is 43.52.
Sales Growth
Air Transport Services Group’s sales growth is 8.8% for the ongoing quarter and 7.6% for the next.
Volume
Today’s last reported volume for Air Transport Services Group is 567715 which is 18.1% above its average volume of 480683.
Moving Average
Air Transport Services Group’s worth is way below its 50-day moving average of $21.89 and way under its 200-day moving average of $26.58.
5. Exelixis (EXEL)
7.1% sales growth and 7.76% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.54.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 35.02. Meaning, the purchaser of the share is investing $35.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.76%.
Yearly Top and Bottom Value
Exelixis’s stock is valued at $18.91 at 16:22 EST, way under its 52-week high of $23.26 and way above its 52-week low of $14.87.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 23.8% and a negative 31.8%, respectively.
Sales Growth
Exelixis’s sales growth is 19.2% for the present quarter and 7.1% for the next.
Moving Average
Exelixis’s worth is above its 50-day moving average of $18.15 and higher than its 200-day moving average of $17.79.
